Valproate Restrictions for Male ‌Patients Under Review Amidst Conflicting Study Data

London, UK – The‌ UK’s Medicines and Healthcare products Regulatory Agency (MHRA)⁢ is reviewing its precautionary measures for male‍ patients taking valproate, a widely used medication for epilepsy and bipolar disorder. These measures, introduced in 2024, aimed to mitigate potential risks to offspring, building upon existing restrictions implemented in 2018 to prevent valproate exposure in pregnant​ women due to known risks ⁢of malformations and developmental⁤ problems.

The MHRA’s 2024 proposal was based on ​findings from a Post-Authorisation Safety Study (PASS). ‍While acknowledging limitations⁢ in the PASS data, the committee at the time concluded that the potential risks warranted informing patients ⁤and healthcare professionals about the need for precautionary measures.

Conflicting Evidence Emerges

However, recent research has cast doubt on the initial findings. A study published in ⁤ JAMA ⁤in June 2024, utilizing a subset of the same⁢ Danish data as the PASS, failed to replicate the reported risks. This study examined 1,235,353 children, with 1,336 born to fathers who had‌ filled prescriptions for valproate during the period​ of spermatogenesis. The researchers⁤ found no association between paternal valproate use and an increased risk of major⁤ congenital malformations or neurodevelopmental disorders (NDDs).

The authors of ⁢the JAMA study highlighted that the original PASS results were derived from⁣ an observational study report prepared‌ by ⁤the⁤ contract research organization IQVIA. “We ⁢were unable to replicate the IQVIA study results,” ​they stated, indicating ‌a significant discrepancy in the data interpretation or methodology.

Latest Research Reinforces No Increased ⁣Risk

Further complicating the picture,the⁢ same research team published a follow-up research letter in JAMA in May 2025. This subsequent analysis was conducted after gaining access to more detailed information about the IQVIA study. By exploring the impact of different methodological choices and definitions used in the original IQVIA report, the researchers aimed to reconcile the conflicting⁢ findings.

Their latest analysis concluded definitively: “Paternal valproate ⁣exposure⁣ was not associated with an⁢ increased risk of NDDs.” ⁤This conclusion ‌remained robust ‍across​ various analyses, including the composite endpoint⁤ of ⁤all NDDs, specific NDDs, expanded definitions of NDDs, ⁤varying valproate doses,⁢ time ‍trends, polytherapy, and analyses specifically restricted to ⁤fathers with epilepsy.

Regulatory Body Initiates Signal Procedure

In light of this latest study, wich coudl not replicate the signal for NDDs in children with paternal valproate exposure, and ⁣a recent systematic review from Australia⁣ that also found “no clear evidence for an⁤ adverse impact of paternal antiseizure medication use on offspring outcomes,” the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has initiated​ a‌ signal procedure.

This procedure‍ is designed to thoroughly investigate the discrepancies in findings across the various studies. ‍The​ PRAC has also ‍formally requested further information and detailed analyses from the marketing authorization holders of valproate. The EMA has indicated that it will provide further updates as more information becomes‌ available, suggesting a potential reassessment ‌of the current⁣ restrictions for male patients taking⁢ valproate.